{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:24:33Z","timestamp":1769837073567,"version":"3.49.0"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2003,1,17]],"date-time":"2003-01-17T00:00:00Z","timestamp":1042761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["pathsocjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pathology"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nuclear expression of the Y\u2010box\u2010binding protein (YB\u20101) has been reported to correlate with the expression of P\u2010glycoprotein in breast cancer and osteosarcoma. Overexpression of the ATP\u2010binding cassette (ABC) superfamily, such as P\u2010glycoprotein\/multi\u2010drug resistance (MDR) 1 and MDR\u2010associated protein (MRP) 1, 2 and 3, has been reported in various malignant neoplasms. Fifty\u2010four surgically resected synovial sarcomas were examined immunohistochemically for nuclear expression of YB\u20101 and intrinsic expression of P\u2010glycoprotein, MRP1, MRP2, and topoisomerase II \u03b1, and the findings were compared with clinicopathological parameters, proliferative activities as evaluated by MIB\u20101 labelling index (LI), and the patients' prognoses. In addition, MDR1, MRP1, MRP2, and MRP3 mRNA levels were assessed using a quantitative reverse transcriptase\u2010polymerase chain reaction (RT\u2010PCR) method in 22 concordant frozen specimens from these cases and the findings were compared with six control skeletal muscle tissues. Independent prognostic factors were investigated using the Cox proportional hazards regression model. Nuclear expression of YB\u20101 protein correlated with P\u2010glycoprotein expression (<jats:italic>p<\/jats:italic> = 0.0126). Moreover, cases with nuclear expression of YB\u20101 correlated with poor survival (<jats:italic>p<\/jats:italic> = 0.0495) and showed a high topoisomerase II \u03b1 labelling index (topo II \u03b1 LI) (<jats:italic>p<\/jats:italic> = 0.0056) and a high MIB\u20101 LI (<jats:italic>p<\/jats:italic> = 0.01). Multivariate Cox analysis showed that only the nuclear expression of YB\u20101 (<jats:italic>p<\/jats:italic> = 0.0136) and high American Joint Committee on Cancer (AJCC) stage (ie stage III or IV) (<jats:italic>p<\/jats:italic> &lt; 0.0001) were independent factors for poor prognosis, while the expression of the YB\u20101 responsive gene products examined was not. These results indicate that the nuclear expression of YB\u20101 protein is associated with P\u2010glycoprotein expression and proliferative activity as shown by the topo II \u03b1 LI and the MIB\u20101 LI, and that expression of this protein is an important independent prognostic factor in synovial sarcoma. Copyright \u00a9 2003 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/path.1282","type":"journal-article","created":{"date-parts":[[2005,1,19]],"date-time":"2005-01-19T09:48:23Z","timestamp":1106128103000},"page":"251-258","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Nuclear expression of Y\u2010box\u2010binding protein\u20101 correlates with P\u2010glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma"],"prefix":"10.1002","volume":"199","author":[{"given":"Yoshinao","family":"Oda","sequence":"first","affiliation":[]},{"given":"Yoshihiro","family":"Ohishi","sequence":"additional","affiliation":[]},{"given":"Tsuyoshi","family":"Saito","sequence":"additional","affiliation":[]},{"given":"Eiji","family":"Hinoshita","sequence":"additional","affiliation":[]},{"given":"Takeshi","family":"Uchiumi","sequence":"additional","affiliation":[]},{"given":"Naoko","family":"Kinukawa","sequence":"additional","affiliation":[]},{"given":"Yukihide","family":"Iwamoto","sequence":"additional","affiliation":[]},{"given":"Kimitoshi","family":"Kohno","sequence":"additional","affiliation":[]},{"given":"Michihiko","family":"Kuwano","sequence":"additional","affiliation":[]},{"given":"Masazumi","family":"Tsuneyoshi","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2003,1,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950170104"},{"key":"e_1_2_6_3_2","first-page":"4224","article-title":"Role of human Y box\u2010binding protein YB\u20101 in cellular sensitivity to the DNA\u2010damaging agents cisplatin, mitomycin C, and ultraviolet light","volume":"56","author":"Ohga T","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0497-447"},{"key":"e_1_2_6_5_2","first-page":"2273","article-title":"Nuclear expression of YB\u20101 protein correlates with P\u2010glycoprotein expression in human osteosarcomas","volume":"4","author":"Oda Y","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<732::AID-IJC6>3.0.CO;2-#"},{"key":"e_1_2_6_7_2","first-page":"2357","article-title":"Expression of Y box\u2010binding protein\u20101 correlates with DNA topoisomerase II \u03b1 and proliferating cell nuclear antigen expression in lung cancer","volume":"21","author":"Gu C","year":"2001","journal-title":"Anticancer Res"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.62.070193.002125"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1360704"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00046-9"},{"key":"e_1_2_6_11_2","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance\u2010associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool M","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_12_2","first-page":"4124","article-title":"A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin\u2010resistant human cancer cell lines with decreased drug accumulation","volume":"56","author":"Taniguchi K","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_6_13_2","first-page":"5475","article-title":"A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells","volume":"57","author":"Koike K","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.6.1219"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)00979-5"},{"key":"e_1_2_6_16_2","first-page":"673","article-title":"Expression of multidrug resistance protein\u2010related genes in lung cancer: correlation with drug response","volume":"5","author":"Young LC","year":"1990","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950130603"},{"key":"e_1_2_6_18_2","first-page":"346","article-title":"DNA topoisomerases and topoisomerase inhibitors","volume":"42","author":"Giaccone G","year":"1994","journal-title":"Pathol Biol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.17.7654"},{"key":"e_1_2_6_20_2","first-page":"1373","article-title":"Single\u2010strand conformational polymorphism analysis of the Mr 170 000 isozyme of DNA topoisomerase II in human tumor cells","volume":"53","author":"Danks MK","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_21_2","first-page":"1666","article-title":"The multidrug sensitivity phenotype of human lung cells associated with topoisomerase II expression","volume":"52","author":"Giaccone G","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.9"},{"key":"e_1_2_6_23_2","first-page":"651","article-title":"Prognostic significance of a formalin\u2010resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki\u2010S1","volume":"142","author":"Kreipe H","year":"1993","journal-title":"Am J Pathol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4781(95)00171-9"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1983.tb02097.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196505)18:5<613::AID-CNCR2820180510>3.0.CO;2-V"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199301000-00004"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2596::AID-CNCR16>3.0.CO;2-K"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2161::AID-CNCR2820720716>3.0.CO;2-2"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.150"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3794"},{"key":"e_1_2_6_33_2","first-page":"1483","volume-title":"Enzinger and Weiss's Soft Tissue Tumors","author":"Weiss SW","year":"2001"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(00)80218-X"},{"key":"e_1_2_6_35_2","first-page":"149","volume-title":"American Joint Committee on Cancer (AJCC) Staging Manual","author":"Fleming ID","year":"1997"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511233332103"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1681::AID-CNCR39>3.0.CO;2-U"},{"key":"e_1_2_6_38_2","first-page":"2401","article-title":"Increased expression of an ATP\u2010binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas","volume":"6","author":"Hinoshita E","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_39_2","first-page":"342","article-title":"Transcription factor Y\u2010box binding protein 1 binds preferentially to cisplatin\u2010modified DNA and interacts with proliferating cell nuclear antigen","volume":"59","author":"Ise T","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204029"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U"},{"key":"e_1_2_6_42_2","first-page":"3151","article-title":"Nuclear expression of the Y\u2010box binding protein, YB\u20101, as a novel marker of disease progression in non\u2010small cell lung cancer","volume":"7","author":"Shibahara K","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.11.5997"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019606-199606000-00004"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01438312"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<976::AID-CNCR12>3.0.CO;2-3"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010515)91:10<1940::AID-CNCR1217>3.0.CO;2-3"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)90457-Q"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058073"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01366956"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(97)90256-2"}],"container-title":["The Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/path.1282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:04:07Z","timestamp":1761051847000},"score":1,"resource":{"primary":{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/10.1002\/path.1282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,17]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1002\/path.1282"],"URL":"https:\/\/doi.org\/10.1002\/path.1282","archive":["Portico"],"relation":{},"ISSN":["0022-3417","1096-9896"],"issn-type":[{"value":"0022-3417","type":"print"},{"value":"1096-9896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,17]]},"assertion":[{"value":"2002-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}